An Open Label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers
Latest Information Update: 10 Oct 2022
At a glance
- Drugs CKD-349 (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 05 Oct 2022 Status changed from recruiting to completed.
- 21 Dec 2021 Planned End Date changed from 6 Dec 2021 to 14 Mar 2022.
- 21 Dec 2021 Planned primary completion date changed from 29 Nov 2021 to 14 Jan 2022.